Peripheral expression of key regulatory kinases in Alzheimer's disease and Parkinson's disease

Neurobiology of Aging

Volumn 32, Issue 12, 2011, Pages 2142-2151

  Armentero, M T ^a   Sinforiani, E ^a   Ghezzi, C ^a   Bazzini, E ^a   Levandis, G ^a   Ambrosi, G ^a   Zangaglia, R ^a   Pacchetti, C ^a   Cereda, C ^a   Cova, E ^a   Basso, E ^a   Celi, D ^b   Martignoni, E ^c   Nappi, G ^a,d   Blandini, F ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Glycogen kinase 3; Neurodegenerative disease; Peripheral blood lymphocytes; Protein kinase B; Tau

Indexed keywords

DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GLYCOGEN SYNTHASE KINASE 3; LEVODOPA; PROTEIN KINASE B; PYRIDOSTIGMINE; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE SEVERITY; ENZYME ANALYSIS; ENZYME LOCALIZATION; FEMALE; HUMAN; HUMAN CELL; MALE; PARKINSON DISEASE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CELLS, CULTURED; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; PARKINSON DISEASE; PROTO-ONCOGENE PROTEINS C-AKT; TAU PROTEINS;

EID: 80053625945     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.01.004     Document Type: Article

References (46)

1. Asuni A.A., Hooper C., Reynolds C.H., Lovestone S., Anderton B.H., Killick R. GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur. J. Neurosci. 2006, 24:3387-3392.
2. Augustinack J.C., Schneider A., Mandelkow E.M., Hyman B.T. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. 2002, 103:26-35.
3. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007, 28:166-172.
4. Blalock E.M., Geddes J.W., Chen K.C., Porter N.M., Markesbery W.R., Landfield P.W. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl. Acad. Sci. USA 2004, 101:2173-2178.
5. Blandini F., Cosentino M., Mangiagalli A., Marino F., Samuele A., Rasini E., Fancellu R., Tassorelli C., Pacchetti C., Martignoni E., Riboldazzi G., Calandrella D., Lecchini S., Frigo G., Nappi G. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J. Neural Transm. 2004, 111:1017-1030.
6. Blandini F., Sinforiani E., Pacchetti C., Samuele A., Bazzini E., Zangaglia R., Nappi G., Martignoni E. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 2006, 66:529-534.
7. Bove J., Prou D., Perier C., Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2005, 2:484-494.
8. Buttrick G.J., Wakefield J.G. PI3-K and GSK-3: Akt-ing together with microtubules. Cell Cycle 2008, 7:2621-2625.
9. Bychkov E., Ahmed M.R., Dalby K.N., Gurevich E.V. Dopamine depletion and subsequent treatment with l-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J. Neurochem. 2007, 102:699-711.
10. Cho J.H., Johnson G.V. Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J. Biol. Chem. 2003, 278:187-193.
11. Cosentino M., Rasini E., Colombo C., Marino F., Blandini F., Ferrari M., Samuele A., Lecchini S., Nappi G., Frigo G. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. Free Radic. Biol. Med. 2004, 36:1233-1240.
12. Dekosky S.T., Ikonomovic M.D., Wang X., Farlow M., Wisniewski S., Lopez O.L., Becker J.T., Saxton J., Klunk W.E., Sweet R., Kaufer D.I., Kamboh M.I. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann. Neurol. 2003, 53:81-90.
13. Dickey C.A., Koren J., Zhang Y.J., Xu Y.F., Jinwal U.K., Birnbaum M.J., Monks B., Sun M., Cheng J.Q., Patterson C., Bailey R.M., Dunmore J., Soresh S., Leon C., Morgan D., Petrucelli L. Akt and CHIP coregulate tau degradation through coordinated interactions. Proc. Natl. Acad. Sci. USA 2008, 105:3622-3627.
14. Duronio V. The life of a cell: apoptosis regulation by the PI3K/PKB pathway. Biochem. J. 2008, 415:333-344.
15. Ferrer I., Barrachina M., Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease. Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol. 2002, 104:583-591.
16. Giese K.P. GSK-3 a player in neurodegeneration and memory. IUBMB Life 2009, 61:516-521.
17. Griffin R.J., Moloney A., Kelliher M., Johnston J.A., Ravid R., Dockery P., O'connor R., O'neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J. Neurochem. 2005, 93:105-117.
18. Hooper C., Killick R., lovestone S. The GSK3 hypothesis of Alzheimer's disease. J. Neurochem. 2008, 104:1433-1439.
19. Hoshi M., Takashima A., Noguchi K., Murayama M., Sato M., Kondo S., Saitoh Y., Ishiguro K., Hoshino T., Imahori K. Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc. Natl. Acad. Sci. USA 1996, 93:2719-2723.
20. Hye A., Kerr F., Archer N., Foy C., Poppe M., Brown R., Hamilton G., Powell J., Anderton B., Lovestone S. Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci. Lett. 2005, 373:1-4.
21. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci. 2004, 29:95-102.
22. Koh S.H., Song C., Noh M.Y., Kim H.Y., Lee K.Y., Lee Y.J., Kim J., Kim S.H., Kim H.T. Inhibition of glycogen synthase kinase-3 reduces l-DOPA-induced neurotoxicity. Toxicology 2008, 247:112-118.
23. Kvetnoy I.M., Hernandez-Yago J., Kvetnaia T.V., Khavinson V.K., Malinin V.V., Yarilin A.A., Sharova N.I., Blesa J.R., Anisimov V.N., Lenskaia L.V., Sluchevskaia S.F., Chekalina S.I., Tokarev O.Y., Yuzhakov V.V. Tau-protein expression in human blood lymphocytes: a promising marker and suitable sample for life-time diagnosis of Alzheimer's disease. Neuro. Endocrinol. Lett. 2000, 21:313-318.
24. Kwok J.B., Hallupp M., Loy C.T., Chan D.K., Woo J., Mellick G.D., Buchanan D.D., Silburn P.A., Halliday G.M., Schofield P.R. GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann. Neurol. 2005, 58:829-839.
25. Lai C.T., Yu P.H. Dopamine and L-B-3,4-dihydroxyphenylalanine Hydrochlorid (l-DOPA)-induced Cytotoxicity towards Catecholaminergic Neuroblastoma SH-SYS5 Cells. Effects of oxidative stress and antioxidative factors. Biochem. Parmacol. 1997, 53:363-372.
26. Lin C.H., Yeh S.H., Lin C.H., Lu K.T., Leu T.H., Chang W.C., Gean P.W. A role for the PI-3 kinase signaling pathway in fear conditioning and synaptic plasticity in the amygdala. Neuron 2001, 31:841-851.
27. Lucas J.J., Hernandez F., Gomez-Ramos P., Moran M.A., Hen R., Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001, 20:27-39.
28. Luna-Munoz J., Garcia-Sierra F., Falcon V., Menendez I., Chavez-Macias L., Mena R. Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease. J. Alzheimers Dis. 2005, 8:29-41.
29. Marksteiner J., Humpel C. Glycogen-synthase kinase-3beta is decreased in peripheral blood mononuclear cells of patients with mild cognitive impairment. Exp. Gerontol. 2009, 44:370-371.
30. Mateo I., Infante J., Llorca J., Rodriguez E., Berciano J., Combarros O. Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 21:228-232.
31. Mckahn G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984, 34:939-944.
32. Mollenhauer B., Trenkwalder C., Von Ahsen N., Bibl M., Steinacker P., Brechlin P., Schindehuette J., Poser S., Wiltfang J., Otto M. Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 2006, 22:200-208.
33. Morfini G., Szebenyi G., Elluru R., Ratner N., Brady S.T. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 2002, 21:281-293.
34. Nagao M., Hayashi H. Glycogen synthase kinase-3beta is associated with Parkinson's disease. Neurosci. Lett. 2009, 449:103-107.
35. Pei J.J., Braak E., Braak H., Grundke-Iqbal I., Iqbal K., Winblad B., Cowburn R.F. Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J. Neuropathol. Exp. Neurol. 1999, 58:1010-1019.
36. Pigino G., Morfini G., Pelsman A., Mattson M.P., Brady S.T., Busciglio J. Alzheimers presenilin 1 mutations impair kinesin-based axonal transport. J. Neurosci. 2003, 23:4499-4508.
37. Plattner F., Angelo M., Giese K.P. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J. Biol. Chem. 2006, 281:25457-25465.
38. Ross C.A., Poirier M.A. Protein aggregation and neurodegenerative disease. Nat. Med. 2004, 10(Suppl.):S10-S17.
39. Serenó L., Coma M., Rodríguez M., Sánchez-Ferrer P., Sánchez M.B., Gich I., Agulló J.M., Pérez M., Avila J., Guardia-Laguarta C., Clarimón J., Lleó A., Gómez-Isla T. A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol. Dis. 2009, 35:359-367.
40. Shah S.B., Nolan R., Davis E., Stokin G.B., Niesman I., Canto I., Glabe C., Goldstein L.S.B. Examination of potential mechanisms of amyloid-induced defects in neuronal transport. Neurobiol. Dis. 2009, 36:11-25.
41. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., Raman R., Davies P., Masliah E., Williams D.S., Goldstein L.S.B. Axonopathy and transport deficits early in the pathogenesis of Alzheimer disease. Science 2005, 307:1282-1288.
42. Telford G., Wilkinson L.J., Hooi D.S.W., Worrall V., Green A.C., Cook D.L., Pritchard D.I., Griffiths G.D. An in vitro investigation of the effects of the nerve agent pretreatment pyridostigmine bormide on human peripheral blood T-cell function. Int. Immunopharmacol. 2004, 4:1455-1466.
43. Timmons S., Coakley M.F., Moloney A.M., O'Neil C. Akt signal transduction dysfunction in Parkinson's disease. Neurosci. Lett. 2009, Oct1. [Epub ahead of print], PMID: 19800394.
44. Uberti D., Lanni C., Racchi M., Govoni S., Memo M. Conformationally altered p53: a putative peripheral marker for Alzheimer's disease. Neurodegener. Dis. 2008, 5:209-211.
45. Valencia A., Reeves P.B., Sapp E., Li X., Alexander J., Kegel K.B., Chase K., Aronin N., DiFiglia M. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J Neurosci Res. 2010, 88:179-190.
46. Xiromerisiou G., Hadjigeorgiou G.M., Papadimitriou A., Katsarogiannis E., Gourbali V., Singleton A.B. Association between AKT1 gene and Parkinson's disease: a protective haplotype. Neurosci. Lett. 2008, 436:232-234.